Intraoral dosage forms of glucagon
View Patent ↗The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
1. A dosage unit form comprising (a) glucagon, and (b) a delivery agent of the formula
and salts thereof, wherein:
Ar is 2-hydroxyphenyl or 2-hydroxynaphthyl;
Ar is optionally substituted with one or more of —OH, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy;
R 7 is selected from C 4 -C 20 alkyl, C 4 -C 20 alkenyl, phenyl, naphthyl, (C 1 -C 10 alkyl) phenyl, (C 2 -C 10 alkenyl)phenyl, (C 1 -C 10 alkyl) naphthyl, (C 2 -C 10 alkenyl)naphthyl, phenyl(C 1 -C 10 alkyl), phenyl(C 2 -C 10 alkenyl), naphthyl(C 1 -C 10 alkyl), or naphthyl(C 2 -C 10 alkenyl);
R 8 is selected from hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;
R 7 is optionally substituted with C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, —OH, —SH, and —CO 2 R 9 , or any combination thereof;
R 9 is hydrogen, C 1 -C 4 alkyl, or C 2 -C 4 alkenyl; and
R 7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof,
wherein the dosage unit form is suitable for intraoral administration.
2. The dosage unit form of claim 1 , wherein the delivery agent is selected from the group consisting of
the monosodium salt of N-(8-[2-hydroxybenzoyl]-amino)caprylic acid,
the monosodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid,
the monosodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid,
the monosodium salt of 8-(2,6-dihydroxybenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-bromobenzoylamino)octanoic acid,
the monosodium salt 8-(2-hydroxy-5-chlorobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-iodobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-methylbenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-fluorobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid,
the disodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid,
the disodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid, and
the disodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid.
3. The dosage unit form of claim 1 wherein the delivery agent is N-(8-[2-hydroxybenzoyl]-amino)caprylic acid or a pharmaceutically acceptable salt thereof.
4. The dosage unit form of claim 1 wherein the delivery agent is N-(10-[2-hydroxybenzoyl]-amino)decanoic acid or a pharmaceutically acceptable salt thereof.
5. A dosage unit form comprising:
(A) the dosage unit form of claim 1 ; and
(B) (a) an excipient,
(b) a diluent,
(c) a disintegrant,
(d) a lubricant,
(e) a plasticizer,
(f) a colorant,
(g) a dosing vehicle, or
(h) any combination thereof.
6. The dosage unit form of claim 5 , wherein the dosage unit form is in the form of a tablet, a capsule, a particle, a powder, a sachet, or a liquid.
7. The dosage unit form of claim 6 , wherein the dosing vehicle is a liquid selected from the group consisting of water, aqueous propylene glycol, phosphate buffer, 1,2-propane diol, ethanol, and any combination thereof.
8. A method for administering an effective amount of glucagon to a patient in need thereof, comprising the step of intraorally administering the dosage unit form according to claim 1 .
9. A method of treating hypoglycemia in a patient in need thereof, comprising the step of intraorally administering to the patient an effective amount of the dosage unit form according to claim 1 .
10. A method of preparing a dosage unit form comprising the step of mixing (a) glucagon, and (b) a delivery agent of the formula
or a salt thereof,
wherein:
Ar is 2-hydroxyphenyl or 2-hydroxynaphthyl;
Ar is optionally substituted with one or more of —OH, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy;
R 7 is selected from C 4 -C 20 alkyl, C 4 -C 20 alkenyl, phenyl, naphthyl, (C 1 -C 10 alkyl) phenyl, (C 2 -C 10 alkenyl)phenyl, (C 1 -C 10 alkyl) naphthyl, (C 2 -C 10 alkenyl)naphthyl, phenyl(C 1 -C 10 alkyl), phenyl(C 2 -C 10 alkenyl), naphthyl(C 1 -C 10 alkyl), or naphthyl(C 2 -C 10 alkenyl);
R 8 is selected from hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;
R 7 is optionally substituted with C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, —OH, —SH, and —CO 2 R 9 , or any combination thereof;
R 9 is hydrogen, C 1 -C 4 alkyl, or C 2 -C 4 alkenyl; and
R 7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof,
wherein the dosage unit form is suitable for intraoral administration.
11. The dosage unit form according to claim 1 containing at least about 0.1 mg to about 1 mg of glucagon with at least about 30 mg to about 100 mg of carrier.
12. A dosage unit form comprising (a) glucagon, and (b) a delivery agent of the formula
and salts thereof, wherein:
Ar is 2-hydroxyphenyl or 2-hydroxynaphthyl;
Ar is optionally substituted with one or more of —OH, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy or C 1 -C 4 haloalkoxy;
R 7 is selected from C 4 -C 20 alkyl, C 4 -C 20 alkenyl, phenyl, naphthyl, (C 1 -C 10 alkyl) phenyl, (C 2 -C 10 alkenyl)phenyl, (C 1 -C 10 alkyl) naphthyl, (C 2 -C 10 alkenyl)naphthyl, phenyl(C 1 -C 10 alkyl), phenyl(C 2 -C 10 alkenyl), naphthyl(C 1 -C 10 alkyl), or naphthyl(C 2 -C 10 alkenyl);
R 8 is selected from hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, and C 1 -C 4 haloalkoxy;
R 7 is optionally substituted with C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, —OH, —SH, and —CO 2 R 9 , or any combination thereof;
R 9 is hydrogen, C 1 -C 4 alkyl, or C 2 -C 4 alkenyl; and
R 7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof,
wherein the dosage unit form is suitable for sublingual administration.
13. The dosage unit form of claim 12 , wherein the delivery agent is selected from the group consisting of
the monosodium salt of N-(8-[2-hydroxybenzoyl]-amino)caprylic acid,
the monosodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid,
the monosodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid,
the monosodium salt of 8-(2,6-dihydroxybenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-bromobenzoylamino)octanoic acid,
the monosodium salt 8-(2-hydroxy-5-chlorobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-iodobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-methylbenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-fluorobenzoylamino)octanoic acid,
the monosodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid,
the disodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid,
the disodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid, and
the disodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid.
14. The dosage unit form of claim 12 , wherein the delivery agent is N-(8-[2-hydroxybenzoyl]-amino)caprylic acid or a pharmaceutically acceptable salt thereof.
15. The dosage unit form of claim 12 , wherein the delivery agent is N-(10-[2-hydroxybenzoyl]-amino)decanoic acid or a pharmaceutically acceptable salt thereof.
16. A method of treating hypoglycemia in a patient in need thereof, comprising the step of sublingually administering to the patient an effective amount of the dosage unit form according to claim 12 .
17. The dosage unit form of claim 1 , wherein the weight ratio of glucagon to delivery agent is about 1:100.
18. The dosage unit form of claim 12 , wherein the weight ratio of glucagon to delivery agent is about 1:100.